PHARMACODYNAMIC INTERACTION BETWEEN TAK-442, AN ORAL DIRECT FACTOR XA INHIBITOR, AND PRASUGREL IN HEALTHY SUBJECTS

被引：0
|
作者：
Wood, Nolan [1 ]
Stringer, Fran [1 ]
Wu, Ruishan [1 ]
Kawamura, Masaki [1 ]
Spaeder, Jeff [1 ]
机构：
[1] Takeda Global Res & Dev Inc, Deerfield, IL USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2011年 / 57卷 / 14期
关键词：
D O I：
10.1016/S0735-1097(11)61504-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E1504 / E1504
页数：1
相关论文
共 50 条
  • [1] The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects
    Stringer, Fran
    Scott, Graham
    Kupfer, Stuart
    Prescott, Kim
    Jenkins, Robert
    Harding, Sarah
    Cao, Charlie
    Kawamura, Masaki
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 305 - 305
  • [2] Absence of pharmacodynamic or pharmacokinetic interactions when TAK-442, an oral, direct factor Xa inhibitor, is co-administered with aspirin or clopidogrel
    Stringer, Fran
    Scott, Graham
    Kupfer, Stuart
    Cao, Charlie
    Kawamura, Masaki
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 299 - 299
  • [3] PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF THE NOVEL ORAL DIRECT FACTOR XA INHIBITOR TAK-442.
    Stringer, F.
    Ploeger, B.
    Scott, G.
    Kawamura, M.
    Kupfer, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S89 - S89
  • [4] Evaluation of interethnic differences in the pharmacokinetics and pharmacodynamics of TAK-442, a novel factor Xa inhibitor, in healthy male Japanese and European subjects
    Okamoto, H.
    Stringer, F.
    Hirayama, M.
    Nakamura, K.
    Nakata, E.
    Minamide, Y.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 107 - 108
  • [5] Pharmacology of an oral factor Xa inhibitor TAK-442: Translational animal models for strategic clinical trials
    Konishi, Noriko
    Hiroe, Katsuhiko
    Kawamura, Masaki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 30P - 30P
  • [6] Antithrombotic profiles of TAK-442, a novel oral factor Xa inhibitor, in venous and arterial thrombosis models
    Konishi, N.
    Hiroe, K.
    Shinozawa, E.
    Shofuda, K.
    Matsuda, K.
    Imaeda, Y.
    Fujimoto, T.
    Kubo, K.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 759 - 760
  • [7] Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome
    Goldstein, Sidney
    Bates, Eric R.
    Bhatt, Deepak L.
    Cao, Charlie
    Holmes, David
    Kupfer, Stuart
    Martinez, Felipe
    Spaeder, Jeffrey
    Weitz, Jeffrey I.
    Ye, Zhan
    Zannad, Faiez
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (06) : 1141 - 1152
  • [8] Comparison of the pharmacokinetics and pharmacodynamics of TAK-442, a novel factor Xa inhibitor, between Japanese acute coronary syndrome patients and healthy Japanese males
    Nakamura, K.
    Okamoto, H.
    Stringer, F.
    Hirayama, M.
    Nakata, E.
    Minamide, Y.
    Kawamura, M.
    Ogawa, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 107 - 107
  • [9] Synergistic effect of TAK-442, a direct factor Xa inhibitor, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats
    Konishi, N.
    Hiroe, K.
    Shinozawa, E.
    Imaeda, Y.
    Kubo, K.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 384 - 385
  • [10] Effects of TAK-442, a direct factor XA inhibitor, and fondaparinux on platelet-associated prothrombinase in the balloon injured artery of rats
    Konishi, N.
    Katsuhiko, H.
    Imaeda, Y.
    Fujimoto, T.
    Kubo, K.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 759 - 759
12345